# A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

> **NCT04353102** · PHASE1 · COMPLETED · sponsor: **Eucure (Beijing) Biopharma Co., Ltd** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** YH002

## Key facts

- **NCT ID:** NCT04353102
- **Lead sponsor:** Eucure (Beijing) Biopharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-22
- **Primary completion:** 2021-09-14
- **Final completion:** 2021-11-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353102, "A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04353102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*